Glucagon-like peptide-1 (GLP-1) medications work. Semaglutide and tirzepatide help people lose more weight than any pill or shot we’ve had before. The harder problem is everything that happens around the drug.
In real-world studies, about a third of patients stop treatment within the first month. In one large insurance claims analysis, only about one in twelve adults who started a GLP-1 for weight loss were still taking it three years later. When people stop, roughly two-thirds of the lost weight comes back within a year. Much of the benefit to the heart and to blood sugar fades with it.
A structured program is there to close that gap. The drug already takes care of the weight loss. A good program has three jobs. It makes sure the weight you lose is mostly fat. It keeps you on treatment long enough for the drug to help. And it helps you hold on to as much of the benefit as possible once you stop.
Start with a real doctor
The features that matter most are also the least exciting. A physician should evaluate you before anyone writes a prescription. That means reviewing your history, running baseline blood work, and checking for the things that make these drugs risky for some people. These include a family history of certain thyroid cancers, past pancreatitis, gallbladder problems, pregnancy, other medications, and any history of disordered eating. A questionnaire will miss some of these. A conversation with a doctor usually catches them.
Real physician voices, twice a week
Free, and one click to unsubscribe.
Ask one simple question: Who can say no? A good program has a clinician who is willing to tell you the drug isn’t right for you, or that a symptom needs a closer look. A program built around sign-ups and refills has different incentives.
Once you start, your dose should be adjusted to how you respond. And someone should pick up the phone when the nausea gets bad in week three.
Protect your muscle
Most of the weight people lose on these drugs is fat, but a meaningful share is lean mass, which includes muscle. Keeping your muscle and strength matters a great deal, especially as you get older.
A serious program tracks more than the number on the scale. Look for:
- Protein targets from the first week
- A resistance training plan
- Body composition measurement when it makes sense
- Regular checks of strength and how well you move day to day
If protein and strength training aren’t in the plan on the day you start, they won’t show up in your results at the end.
Plan for the day you stop
Almost no program advertises this, and it may be the most important feature of all. At some point you will probably come off the medication. It might be your choice, or it might come down to cost, side effects, or supply. That moment is where most of the regained weight comes from. A program that cares about your outcome plans for that day from the very beginning.
Where coaching fits
Many programs sell coaching, so it helps to be clear about what it does. In clinical trials, some people on semaglutide got intensive support: a dozen dietitian visits and a structured diet. Over a little more than a year, they lost about 16 percent of their body weight. People on the same drug with lighter support lost about 15 percent. The drug drove most of the result.
Coaching earns its place over the long run. While the medication keeps your appetite low and food thoughts quiet, you have a good window to build eating and exercise habits, hold on to muscle, and prepare for life after the drug.
I want to be careful here. We have strong evidence that GLP-1s work, that many people stop taking them, and that weight often returns afterward. We don’t yet have equally strong evidence that any particular coaching model breaks that cycle. The next round of studies needs to show that. In my clinical experience, coaching aimed at making results last is still worth having. That’s a more modest claim than most marketing makes, and it’s the one I’d stand behind.
Questions to ask before you sign up
When you compare programs, keep one question in mind. Was this program built around your long-term outcome, or around the fastest route to a prescription?
These questions will tell you which:
- Who is the supervising physician, and when will I talk to them?
- When are my weight, side effects, and labs reviewed, and by whom? Refill reminders don’t count.
- How do you track muscle and strength, beyond my weight?
- What happens if I stop the medication?
- Which medication am I getting? Is it a brand-name product or a compounded version? Who makes it, and what’s the backup plan if it becomes unavailable?
- Why this specific drug for my goals? Several GLP-1 medications are available now. When a program offers only one and calls it the best, that’s a business decision.
Some programs can’t name their doctor, can’t show you scheduled follow-up with a real person, and can’t tell you what happens in month six or month twenty-four. With those, you’re buying a prescription with an app attached.
A note on what’s next
I’m cautiously optimistic about early research on GLP-1s for heart health, brain health, addiction, and sleep apnea. That optimism is a reason to ask for more medical oversight, because every new use brings new unknowns.
The best programs act like they plan to still be your partner a year from now.
Neil Panchal is a board-certified emergency physician and the cofounder and chief medical officer of Longevitix, where he builds the clinical and AI infrastructure behind precision longevity medicine.
He trained in emergency medicine at Mount Sinai in New York City and completed agentic AI training with the Harvard Data Science Institute and Stanford Medicine. His clinical affiliations include Yale New Haven Health, Hackensack Meridian Health, and Atlantic Health. He has spent his career where acute medicine meets prevention, treating the downstream failures of chronic disease that earlier risk stratification could have prevented.
At Longevitix, he directs the clinical evidence engine. He translates clinical research, biomarkers, wearables, and multimodal data into personalized protocols, and he sets the standards that govern how AI applies to physician workflows and patient care. His work spans healthspan optimization, early disease detection, and clinical decision support, pairing frontline medical judgment with health informatics.
He writes and speaks on evidence-based longevity, preventive medicine, and the responsible deployment of AI in clinical practice, with recent work including peer-reviewed research, commentary on physician oversight of agentic AI, and writing on KevinMD. He also publishes on the Longevitix blog and shares updates on LinkedIn, where Longevitix maintains a company page as well.
